SCHEMBL7054419

SCHEMBL7054419

CCOC(=O)/C(CN1CCCCC1)=N\O

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.60
HTT P42858 1/20 0.60
APOBEC3A P31941 1/20 0.41
APOBEC3G Q9HC16 1/20 0.41
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.36
HSD17B10 Q99714 1/20 0.36
TDP1 Q9NUW8 3/20 0.36
NPC1 O15118 1/20 0.36
KDM4E B2RXH2 3/20 0.36
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7054422 1.00 ALDH1A1 (0.60) ALDH1A1HTTAPOBEC3AAPOBEC3GMEN1
SCHEMBL7058008 0.84 TSHR (0.47) ALDH1A1HTTKMT2ALMNAGAA
SCHEMBL7058013 0.84 TSHR (0.47) ALDH1A1HTTKMT2ALMNAGAA
SCHEMBL7052338 0.83 ALDH1A1 (0.41) ALDH1A1HTTAPOBEC3AAPOBEC3GMEN1
SCHEMBL7057211 0.83 ALDH1A1 (0.41) ALDH1A1HTTAPOBEC3AAPOBEC3GGAA
SCHEMBL7052334 0.83 ALDH1A1 (0.41) ALDH1A1HTTAPOBEC3AAPOBEC3GMEN1
SCHEMBL7057215 0.83 ALDH1A1 (0.41) ALDH1A1HTTAPOBEC3AAPOBEC3GGAA
SCHEMBL7058623 0.76 MEN1 (0.54) ALDH1A1MEN1KMT2ALMNAGAA
SCHEMBL7058622 0.76 MEN1 (0.54) ALDH1A1MEN1KMT2ALMNAGAA
SCHEMBL2038297 0.76 GAA (0.41) ALDH1A1HTTMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608196-B2 Structurally diverse; parallel approach GALILEO PHARMACEUTICALS, INC. 2003-08-19 US disclosed
US-20030100750-A1 Process for solid supported synthesis of pyruvate-derived compounds EDISON PHARMACEUTICALS, INC. 2003-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100750-A1 Process for solid supported synthesis of pyruvate-derived compounds PC, PDK4, PDK1 ALDH1A1 3046/4885HTT 2689/4885APOBEC3A 3073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.